Cantor Fitzgerald analyst Manish Somaiya raised the firm’s price target on Ameresco (AMRC) to $45 from $41 and keeps an Overweight rating on the shares. Ameresco is seeing only modest top-line changes following the Neogenyx joint venture closing, but reported EPS and EBITDA revisions are driven primarily by accounting and minority-interest effects rather than any deterioration in the core business, with management reiterating that the underlying operating outlook remains intact despite a slightly mixed FY26-FY27 earnings translation, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRC:
- Ameresco Forms Neogenyx Fuels Biofuels Joint Venture
- Ameresco price target raised to $59 from $50 at Canaccord
- Ameresco Faces Broad and Emerging Risks Beyond 2025 Form 10-K Disclosures
- Ameresco price target lowered to $36 from $44 at Baird
- Ameresco Earnings Call Highlights Transformative Growth Path
